Cell & Gene
Cell & Gene Therapies: An Overview Of FDA Regulatory Considerations For 2024
April 17, 2024
In an explicit effort to bring approved cell and gene therapies (CGT) to patients sooner, FDA has launched a number of initiatives and programs to address the pace of CGT approvals. In this article for Cell & Gene, Sidley’s Emily Marden and Kelly Cho share their insights on key regulatory developments relevant to sponsors seeking regulatory approval of CGTs for commercialization in the U.S.
View article here.
Contacts
Capabilities
Suggested News & Insights
EU Pharma Package: Sharp New Tools With Limited ProtectionsDecember 18, 2025First Chair Trial and Leading Product Liability Lawyer Paul Boehm Joins Sidley as Partner in D.C. to Expand Product Liability and Mass Torts Litigation PracticeDecember 18, 2025EU Biotech Act: EU Proposes First Set of Rules to Facilitate Biopharmaceutical CompetitivenessThursday, December 18, 2025Sidley Represents Changchun GeneScience (GenSci) Pharmaceuticals in Its Strategic Licensing Agreement With Yarrow Bioscience for First-in-Class Autoimmune Thyroid Disease TherapyDecember 18, 2025Sidley Secures Plan Confirmation in Prospect Medical Holdings' US$2.3 Billion Chapter 11 CaseDecember 17, 2025Sidley Represents Apollo Funds in Majority Investment in Prosol GroupDecember 16, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory